Xeltis

New YouTube video alert!   At Xeltis, we are transforming the treatment paradigm for major life-threatening diseases with our Endogenous Tissue Restoration technology.   #aXess is our restorative vascular access conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access.   We recently received FDA approval for an Investigational Device Exemption (IDE) submission to begin enrolling patients into a pivotal study in the US for aXess.   Combining the safety and patency of a fistula with the speed to treatment of an AV graft, the aXess vascular access conduit offers an improved patient dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by renal disease patients.   Watch our latest video on YouTube via the link below for more information, and subscribe to our channel for more!   #youtube #vascularaccess #hemodialysis

I am thrilled to be joining a panel at the upcoming #LSIEurope24 conference to discuss navigating cross-border business development and licensing in MedTech for successful international deals.   Looking forward to connecting with you all there and do get in touch if you want to arrange a meeting with the team!

What a year it has been so far for Xeltis!   Here are six highlights from the past six months:   ✅ We received IDE approval from the FDA for a US pivotal trial and reached the landmark milestone of >120 patients who have been treated using our technology! 👨💼 We welcomed Shawn M. Gage, PA-C, who joined us to spearhead our clinical trial strategy over the pond. 📖 We had exceptional six-month and twelve-month data from our FIH EU trial for aXess, our restorative vascular access conduit, published in the Journal of Vascular Access and presented at the CX Symposium 2024 👩💻Our CEO Eliane Schutte appeared on Optimum TV to discuss aXess and its potential to transform the lives of dialysis patients with end-stage kidney disease. 🥈 We were awarded Silver rating by corporate sustainability platform EcoVadis for our ESG program and actions. 📺 We launched our YouTube channel!   All of this and much, much more!   Thank you to our dedicated and hardworking team who have made this possible - here's to a successful rest of the year!   #vascularaccess #hemodialysis #Xeltis

Looking forward to being a part of the #LSIEurope24 conference, where I will join a panel to share my insights on how international investor partnerships can drive the global growth of MedTech startups.   Please get in touch if you would like to connect @LSI!

Attention to our Dutch-speaking followers!   Our CEO Eliane Schutte recently had the pleasure of being interviewed for the latest episode of the Leaders in Life Sciences Podcast!   Eliane offered insights into her career journey, Xeltis and its transformative Endogenous Tissue Restoration (ETR) technology, the wider concept of #restorative vessels and the associated benefits, and the regulatory landscape of medical devices.   Have a listen here: https://lnkd.in/ex_4hcjW   #LeadersinLifeSciences #podcast #vascularaccess

Xeltis is officially on YouTube!   Our first video below provides an introduction to #Xeltis and our Endogenous tissue restoration (ETR) technology. Backed by Nobel-prize winning science, our transformative vascular implants are transforming the treatment outlook for major life-threatening diseases.   Subscribe to our channel via the link below. Stay tuned over the coming weeks to see what else we have in store!   #vascularaccess #hemodialysis #youtube

Corporate sustainability platform EcoVadis recently assessed our ESG program and actions, placing us in the top 11% of companies rated by EcoVadis. This awards Xeltis a Silver rating - reflecting our deep commitment to social and environmental responsibility.   On all topics of assessment, Xeltis scored higher than the average industry score - congratulations to our fantastic team who have made this possible.   #sustainability #ESG #environment

We are pleased to announce the appointment of Shawn M. Gage, PA-C as our new Vice President of US Clinical Affairs at Xeltis.   Shawn brings nearly two decades of clinical experience in hemodialysis and vascular access, having previously worked as a vascular surgeon. He co-founded InnAVasc Medical and, as Director of Clinical Operations, was instrumental in the advancement of their hemodialysis graft into phase I/II human clinical trials.   This appointment comes at a pivotal time for Xeltis, as we initiate our US pivotal trial for aXess, our restorative vascular access conduit. Shawn's extensive experience in designing and implementing clinical trials makes him the ideal leader for our US pivotal trial strategy following our recent IDE approval. For more information, read the press release in the comments below. #VascularAccess #Hemodialysis #IDEApproval

Today, Xeltis announces that the FDA has approved an Investigational Device Exemption (IDE) submission to begin enrolling patients in a pivotal study for #aXess.   This US-based pivotal trial follows strong 12-month data from a first-in-human study in Europe and marks a significant milestone in the company's clinical strategy.   aXess is a restorative conduit that allows the formation of a new living vessel for hemodialysis vascular access, providing a better dialysis patient experience. To learn more about the aXess US pivotal trial, see the press release in the comments section below. #FDA #VascularAccess #IDE

Xeltis CEO Eliane Schutte was interviewed by Optimum Strategic Communications as part of #OptimumTV.   In her conversation with Stephen Adams, Eliane discussed Xeltis' Vascular access conduit, aXess, and its potential to transform the lives of dialysis patients with end-stage kidney disease.   She highlighted the self-healing properties of Xeltis' implants and addressed the complications associated with current treatment options. Additionally, Eliane spoke about Xeltis' strategic partnerships, including with DaVita Kidney Care, and the transformative potential of #regenerative medicine in revolutionizing patient treatments and implant delivery.   Watch Eliane's episode below!